Dr. Van Cutsem on Primary Findings from the SPOTLIGHT and GLOW Trials in Metastatic Gastric CancerFebruary 27th 2023
Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.
TTFields With Chemotherapy Under Investigation in Locally Advanced Pancreatic Cancer
Tumor treating fields concomitant with gemcitabine and nab-paclitaxel is being compared with chemotherapy alone in the frontline treatment of patients with aggressive, locally advanced pancreatic cancer as part of the phase 3 PANOVA-3 trial.
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRCJanuary 22nd 2023
The addition of mFOLFOX6 or FOLFIRI to the combination of encorafenib and cetuximab elicited encouraging antitumor activity and safety in patients with BRAF V600E-mutant metastatic colorectal cancer.
Patient-specific Marker Tracking Approach May Better Detect MRD in CRCJanuary 22nd 2023
A novel Burning Rock patient-specific prognostic and potential therapeutic marker tracking approach demonstrated improved sensitivity in detecting circulating tumor DNA and identifying molecular residual disease compared with other approaches in patients with colorectal cancer following surgery.
ctDNA Could Assist in Early Response Assessment in Advanced CRCJanuary 22nd 2023
Circulating tumor DNA could serve as an ideal biomarker to assess early response in patients with advanced colorectal cancer due to its short half-life compared with other tumor biomarkers, and it could enable the use of adaptive clinical study designs in the future.
Dr. Wainberg on Liposomal Irinotecan/NALIRIFOX vs Nab-paclitaxel/Gemcitabine in PDACJanuary 22nd 2023
Zev A. Wainberg, MD, discusses the evaluation of liposomal irinotecan plus 5-fluorouracil leucovorin, and oxaliplatin vs nab-paclitaxel plus gemcitabine in the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.
Neoadjuvant Chemoradiation Plus Veliparib or Pembrolizumab Fails to Improve NAR Score in Locally Advanced Rectal Cancer
Both veliparib plus total neoadjuvant therapy and pembrolizumab plus total neoadjuvant therapy failed to improve short-term outcomes in unselected patients with locally advanced rectal cancer.
Bevacizumab Plus TAS-102 Increases Survival and DCR in mCRCJanuary 21st 2023
Third-line bevacizumab plus trifluridine/tipiracil demonstrated a survival and disease control benefit vs trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer and all clinically relevant subgroups.
Dr. Tabernero on the Efficacy of Bevacizumab Plus TAS-102 in Refractory mCRCJanuary 21st 2023
Josep Tabernero, MD, PhD, discusses findings from the phase 3 SUNLIGHT trial investigating the combination of bevacizumab plus trifluridine/tipiracil vs TAS-102 alone in patients with refractory metastatic colorectal cancer.
Dr. Dawson on the Addition of SBRT to Sorafenib in Locally Advanced HCCJanuary 21st 2023
Laura Dawson, MD, FRCPC, discusses results from the phase 3 NRG/RTOG 1112 trial of stereotactic body radiation therapy plus sorafenib compared with sorafenib alone in patients with locally advanced hepatocellular carcinoma.
CD40-Directed SEA-CD40 Combo Denotes Antitumor Activity in Pancreatic Ductal AdenocarcinomaJanuary 21st 2023
The combination of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab demonstrated early evidence of efficacy in patients with metastatic pancreatic ductal adenocarcinoma, according to updated results from the phase 1 SGNS40-001 study.
Modest Clinical Benefit Is Observed With or Without Bevacizumab Added to Atezolizumab/Chemotherapy in BTC Signal Seeking StudyJanuary 21st 2023
Treatment with or without bevacizumab added to atezolizumab plus cisplatin/gemcitabine demonstrated a modest clinical benefit for patients with advanced biliary tract cancer.
Sorafenib Plus SBRT Improves Survival in Locally Advanced HCCJanuary 21st 2023
The addition of stereotactic body radiation therapy to sorafenib led to an improvement in overall survival, progression-free survival, and time to disease progression compared with sorafenib alone in patients with locally advanced, hepatocellular carcinoma.
Nab-Paclitaxel Plus Gemcitabine/Cisplatin Does Not Significantly Improve OS in Newly Diagnosed, Advanced Biliary Tract Cancers
The addition of nab-paclitaxel to gemcitabine and cisplatin did not result in a statistically significant improvement in overall survival over gemcitabine/cisplatin alone in patients with newly diagnosed, advanced biliary tract cancers.
Frontline NALIRIFOX Elicits OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma
First-line treatment with the combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin produced a clinically meaningful and statistically significant improvement in overall survival and progression-free survival vs nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma, according to results from the phase 3 NAPOLI 3 trial.
Dr. Shitara on Zolbetuximab Plus mFOLFOX6 in CLDN18.2+, HER2– Gastric/GEJ AdenocarcinomaJanuary 20th 2023
Kohei Shitara, MD, discusses the evaluation of the combination of zolbetuximab plus mFOLFOX6 in patients with CLDN18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Dr. Shroff on Results of the SWOG 1815 Trial in Advanced Biliary Tract CancersJanuary 20th 2023
Rachna T. Shroff, MD, MS, discusses efficacy data from the phase 3 SWOG 1815 trial investigating nab-paclitaxel plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in newly diagnosed patients with advanced biliary tract cancers.
bTACE Plus Lenvatinib and MWA Produces Responses, Tolerability in HCCJanuary 20th 2023
Blank-microsphere transarterial chemoembolization plus low-dose lenvatinib and sequential microwave ablation elicited responses and a tolerable safety profile in patients with large hepatocellular carcinoma.
Promising Efficacy and Safety Demonstrated With Envafolimab, Lenvatinib, and TACE in Unresectable HCCJanuary 20th 2023
Findings from the phase 2 CISLC-12 study show favorable safety and efficacy signals for patients with unresectable hepatocellular carcinoma treated with the combination of envafolimab, lenvatinib, and transarterial chemoembolization.
Anti-drug Antibodies Do Not Affect Durvalumab Alone, With Tremelimumab in Unresectable HCC
The presence of anti-drug antibodies appeared to have no effect on efficacy or safety of durvalumab monotherapy or the STRIDE combination of durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma.
LEAP-002 HRQOL Analysis Shows Comparable Scores with Pembrolizumab/Lenvatinib Vs Lenvatinib/Placebo in HCCJanuary 20th 2023
In the first-line treatment of patients with advanced hepatocellular carcinoma, a combination of pembrolizumab plus lenvatinib yielded similar health-related quality of life scores as lenvatinib plus placebo, according to a HRQOL analysis of the phase 3 LEAP-002 study.
Early Exploration With HER-Vaxx Extends Survival for Patients with HER2+ Gastric/GEJ Adenocarcinoma
Patients with HER2-overexpressing metastatic or advanced gastric/gastroesophageal junction adenocarcinoma treated with HER-Vaxx plus standard-of-care chemotherapy had a statistically significant survival benefit compared with those who received chemotherapy alone.
Frontline Zolbetuximab/mFOLFOX6 Prolongs Survival in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
Frontline zolbetuximab plus mFOLFOX6 significantly improved progression-free and overall survival vs placebo/mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, according to primary phase 3 data from the SPOTLIGHT trial.
Nivolumab Plus Ipilimumab or Chemo Maintains OS Benefit in ESCC in Long-Term Results
Nivolumab in combination with chemotherapy or ipilimumab maintained a clinically meaningful overall survival benefit vs chemotherapy alone in patients with treatment-naïve advanced esophageal squamous cell carcinoma.
Updated CheckMate-649 Data Support Nivolumab/Chemo as Frontline SOC in Advanced Gastric/GEJ/Esophageal Cancer
The combination of nivolumab (Opdivo) and chemotherapy continued to provide a clinically meaningful long-term survival benefit and deeper responses than chemotherapy alone in previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, according to 3-year follow-up data from the phase 3 CheckMate-649 trial.